Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Veliparib in Advanced Solid Tumors and Lymphoma
NCT03061188Phase 1Completed
- Sponsor
- Northwestern University
- Start
- May 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of veliparib in solid tumor (advanced stage), non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL) and 1 more, sponsored by Northwestern University. Primary endpoint: Maximum Tolerated Dose at 28 days. Started May 2017; status: completed.
02
Drugs
veliparib
03
Conditions
solid tumor (advanced stage)non-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)T-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT03061188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03061188.